Immune-related endocrine disorders in novel immune checkpoint inhibition therapy  by Min, Le
Genes & Diseases (2016) 3, 252e256Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /ees.elsevier .com/gendis/default .aspREVIEW ARTICLEImmune-related endocrine disorders in
novel immune checkpoint inhibition therapy
Le MinDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, 221 Longwood
Avenue, Boston, MA, 02115, USAReceived 7 September 2016; accepted 12 October 2016
Available online 26 October 2016KEYWORDS
Cancer;
Hypophysitis;
Immune checkpoint
inhibition;
Immune-related
adverse events;
ThyroiditisE-mail address: lmin@bwh.harvard
Peer review under responsibility o
http://dx.doi.org/10.1016/j.gendis.2
2352-3042/Copyright ª 2016, Chongqi
CC BY-NC-ND license (http://creativeAbstract Immune checkpoint inhibition against advance malignancies was named break-
through discovery by the science magazine in 2013. In numerous clinical studies, monoclonal
antibodies against the immune checkpoints, CTLA4, PD1 and PD1 ligand PDL1 have shown
promising tumor response in different type of metastatic malignancies. The adverse events
are autoimmune-related. The endocrine disorders, hypophysitis and thyroiditis are among
the most common side effects associated with immune checkpoint inhibition treatment. Hy-
pophysitis, a very rare endocrine disorder occurs in about one tenth of the patients
receiving anti-CTLA4 treatment. Thyroiditis, on the other hand, is more commonly seen in
patients receiving anti-PD1 treatment. In addition, both thyroiditis and hypophysitis are
common in patients receiving combination treatment with anti-CTLA4 and anti-PD1 treat-
ment. The time to onset of hypophysitis and thyroiditis is short. Most of the endocrine dis-
orders occur within 12 weeks after initiation of the immune checkpoint inhibition therapy.
Hypophysitis can manifest as total anterior pituitary hormone deficiency or isolated pitui-
tary hormone deficiency. Diabetes insipidus is rare. TSH and gonadotropin deficiencies
may be reversible but ACTH deficiency appears permanent. Thyroiditis can present as hypo-
thyroidism or thyrotoxicosis followed by hypothyroidism. Hypothyroidism appears irrevers-
ible. Early identifying the onset of hypophysitis and thyroiditis and proper management of
these endocrine disorders will improve the quality of the life and the outcome of this novel
immunotherapy.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/)..edu.
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Immune system regulation is through immune checkpoints
expressing on the T lymphocytes to stimulate or inhibit T
cell activity.1 Alternation of the checkpoint function results
in disruption of the balance between co-stimulator and
inhibitory signaling in T cells leading to change T cell ac-
tivity. For instance, knockout cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4), an inhibitory immune
checkpoint, in mice caused T cell activation and lympho-
proliferative disorders.2 CTLA4 null mice die at an age of
2e3 weeks due to massive lymphoproliferation. In contrast,
the phenotype of program death-1 (PD-1) deletion mice
appears more mild. The mice developed and grew nor-
mally.3 Although the thymus was apparently normal, PD-1
deletion mice had splenomegaly. Biochemical tests show
increased levels of subset of immunoglobulins, IgG2b, IgA
and most strikingly IgG3. The phenotype of PD-1 deletion
mice supports the role of PD1 in the negative regulation for
subset of B cell proliferation and differentiation including
class switching.3
Over a century’s efforts4 searching for immunotherapy
to augment our own immune system to fight against cancer
have finally reach a breakthrough discovery when a hu-
manized monoclonal antibody against immune checkpoint
CTLA4, ipilimumab demonstrated effective and durable
anticancer activity in patients with metastatic melanoma.5
In 2011, FDA has approved ipilimumab as the first immune
checkpoint inhibitor to treat metastatic melanoma. In
2013, the Science Magazine name cancer immunotherapy
“the breakthrough of the year”.6 Following the success of
anti-CTLA4 therapy in melanoma, the clinical trials
exploring the anticancer efficacy by anti-PD1 and anti-PDL1
demonstrated promising outcome. In 2014 and 2015, two
anti-PD1 agents nivolumab and pembrolizumab received
FDA approval to treat metastatic melanoma and other
metastatic malignancy. More clinical trials are undergoing
to explore the combination anti-PD1 and anti-CTLA4 ther-
apy. Not surprisingly, combination therapy resulted in
higher tumor respond rate.7
Immune checkpoint blockade therapy represents a
major success in cancer therapy, yet this novel treatment is
associated with a unique spectrum of adverse events that
are mostly immune-related adverse events (irAEs). Among
irAEs, immune-related endocrinopathies including hypo-
physitis and thyroid disorders are common.8 Early recogni-
tion and proper management of these endocrinopathies are
important for the oncologists, endocrinologists and other
clinicians to safely use these immune checkpoint inhibitors.
The goal of this review is to describe the clinical manifes-
tations and management of hypophysitis and thyroid dis-
orders associated with anti-CTLA4 and anti-PD1 as
monotherapy or combination therapy. The rare endocrine
disorders such as autoimmune diabetes as well as hyper-
calcemia will be briefly discussed.
Hypophysitis
Hypophysitis, the inflammation of the pituitary, emerged to
be one of the most common irAEs in patient receiving anti-
CTLA4 treatment. The incidence of hypophysitis rangedfrom 0 to 17% in earlier studies.9 Recent cohort studies from
our institution,10 Massachusetts General Hospital,11 and
Memorial Sloan Kettering Cancer Center12 show consistent
high incidence (8e13%). The higher incidence reported in
recent studies suggests the increased awareness of this rare
disease that occurs in 1 per 9 million per year13 in general
population. The incidence of hypophysitis is low in patients
receiving anti-PD1 treatment, less than 1% in most of the
clinical studies.8,14 On the other hand, the incidence of
hypophysitis in the combination therapy is higher8 or com-
parable to the incidence in patients receiving anti-CTLA4
treatment.12 Unlike sporadic hypophysitis, anti-CTLA4-
related hypophysitis is more commonly reported in male
patients. In our study, the incidence of hypophysitis in pa-
tients received ipilimumab treatment was 16% in male and
8.7% in female respectively.10 A higher male to female ratio
(11:8) was reported in a different study.12 The mechanism
underlying anti-CTLA4-related hypophysitis remains to be
elucidated but a recent study displayed that pituitary
glands expressed CTLA-4, particularly in a subset of pro-
lactin- and thyrotropin-secreting cells. These cells became
the site of complement activation, featuring deposition of
C3d and C4d components and an inflammatory cascade
similar to that seen in type II hypersensitivity.15
Since anti-CTLA4-related hypophysitis is a manageable
adverse event, early identification of this potential life
threatening condition warrants timely initiation of the
proper management to improve the outcome and quality of
life in patients receiving anti-CTLA4 treatment and devel-
oped hypophysitis. The symptoms of hypophysitis are
nonspecific. Fatigue and headache are most common
symptoms as initial manifestation of hypophysitis.11 The
median onset of hypophysitis after initiation of anti-CTLA4
treatment is 8e9 weeks.10e12,16 Because anti-CTLA4 treat-
ment is usually given every 3 weeks, most anti-CTLA4-
related hypophysitis occur after 2e3 cycles of the
treatments.
Pituitary is the master gland that secrets hormones to
regulate the downstream endocrine organ function and the
hormone production from the targeted endocrine organs.
Anterior pituitary secrets corticotropin (ACTH) to regulate
cortisol production from the adrenal glands, thyrotropin
(TSH) to regulate thyroxine production from thyroid, go-
nadotropins (LH and FSH) to regulate the function of go-
nads, and growth hormone (GH) to regulate muscle,
adipose and bone metabolism; prolactin to regulate milk
production. Posterior pituitary produce arginine vaso-
pressin to regulate fluid volume homeostasis and oxytocin
to regulate labor process. Anti-CTLA4-related hypophysitis
mainly causes anterior pituitary hormone deficiency,10,16
while posterior hormone deficiency as manifestation of
diabetes insipidus is rarely reported. Ipilimumab-related
hypophysitis can manifest as either isolated or pan-
anterior pituitary hormone deficiency.9,10,16,17 Among the
anterior pituitary hormones, ACTH and TSH deficiencies are
most common.10,16,17 The mechanisms of selective damage
to subgroups of pituitary cells remain to be decoded but the
high incidence of destructive injury to pituitary cortico-
trophs and thyrotrophs secondary to anti-CTLA4-related
hypophysitis underscores the importance of vigilant
monitor of adrenal and thyroid functions after the patients
are initiated with anti-CTLA4 therapy. It is important to
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pituitary hormone deficiency may recover while central
adrenal insufficiency appears permanent.10 Hyponatremia
is common in patients developed anti-CTLA4-related
hypophysitis,10,16 which usually resolved after replace-
ment of hormones for adrenal and thyroid hypo-
function.10,11 Pituitary enlargement in brain MRI is
appreciated in majority of the patients who developed
hypophysitis.10,16 Besides hypophysitis, the differentials for
an enlarged pituitary include metastasis to the pituitary.
While a pituitary biopsy can help to make the diagnosis but
there has been no reported pituitary biopsy performed in
patients who developed anti-CTLA4-related pituitary
enlargement. The biopsy is usually not indicated because
most of the enlarged pituitary normalized in size in a few
weeks.16 Indeed, the dynamic changes of the pituitary
morphology as shown in Fig. 1 supports an inflammatory
process rather than metastatic disease.
The core of the management strategy is the hormone
replacement in anti-CTLA4-related hypophysitis. Although
high dose of glucocorticoid is recommended as a standard
treatment for anti-CTLA4-related hypophysitis in several
literatures,18e20 we did not find that high dose glucocorti-
coid improved the outcome of anti-CTLA4-related hypo-
physitis in our recent cohort study.10 We recommend
replacement dose of glucocorticoid in most patients with
anti-CTLA4-related hypophysitis and central adrenal insuf-
ficiency. We reserve the high dose glucocorticoid treatment
for patients with severe hyponatremia, severe illness such
as sepsis and shock, or patient is undergoing major surgery.
Headache, a common manifestation, can be severe. Usu-
ally, glucocorticoid replacement relieves the headaches in
several days. High dose glucocorticoid is indicated in pa-
tients with persistent severe headache. Replace thyroid
hormone in patients who develop central hypothyroidism
after non-thyroidal illness is ruled out. Initiate testosterone
replacement in male patients with persistent low testos-
terone if not contraindicated. Replacement estrogen in
female hypogonadotropic hypogonadism is controversial for
the concern that estrogen increases coagulopathies and isFig. 1 Dynamic change of pituitary size in brain MRI. A 55-year
headache and fatigue. He had history of hypothyroidism. He had be
trial of ipilimumab, an anti-CTLA4 monoclonal antibody, therapy.
infusions of ipilimumab, he noted headache and fatigue. He denied
were normal 1 week prior to his first ipilimumab infusion. After 3
normal. He is compliant with his levothyroxine. Both his morning
showed pituitary enlargement (B). Prior to the initiation of ipilimum
with hydrocortisone replacement. Six weeks after replacement of h
normalized in size (C).contraindicated in several malignancies such as breast
cancer. Obviously, growth hormone replacement is con-
traindicated in patients with active malignancies. Hypona-
tremia usually resolves shortly after hormone replacement.Thyroid disorders
Anti-PD1 and anti-PDL1 are second generation of immune
checkpoint inhibitors. The mechanisms that PD1 regulates
immune response is different from that of CTLA4 although
both negatively regulate T-cell activity. CTLA4 is expressed
exclusively on T cells where it counteracts the activity of
the T cell co-stimulatory receptor, CD28.21 CD28 mediated
intracellular signaling cascades strongly augments T-cell
receptor signaling to activate T cells but it does not affect T
cell activation unless the T-cell receptor is first engaged by
cognate antigen presented by antigen-presenting cells.
CTLA4 attenuate CD28 mediated T-cell activation by out-
competing CD28 in binding with the shared ligands: CD80
and CD86,22,23 the ligands from antigen presenting cells
that bind to and activate T-cell through CD28 signaling.
PD1, like CTLA4, expresses on the membrane of T-cells.
Unlike CTLA4, which negatively regulates antigen-
presenting cell-mediated T-cell activity, PD1 inhibits T-
cells activity in peripheral tissues. The two ligands for PD1
are PD1 ligand 1 (PDL1) and PD1 ligand 2 (PDL2), while both
ligands express in the peripheral tissues.24e26 During an
inflammatory response, PD1 ligands from peripheral tissues
interact with PD1 to limit autoimmunity.24,27e29 The inter-
action between PD1 and its ligands plays a key role in im-
mune tolerance within the tumor microenvironment30,31
that helps the tumor cells to escape immune attack.
Briefly, PD1 expression is induced when T cells are acti-
vated. When PD1 binds with its ligands, it inhibits T cell
activation.32 Interestingly, the incidence and pattern of
PD1 or PDL1 blockade-associated endocrinopathies are
different from those of CTLA4 blockade. Anti-PD1 treat-
ment is associated with higher incidence of thyroid disorder
that anti-CTLA4 treatment, yet combination therapy withold male with history of metastatic melanoma presented with
en on stable levothyroxine dose for 1 year. He was on a clinical
He received the ipilimumab infusion every 3 weeks. After 3
palpitations, tremors and heat intolerance. His TSH and free T4
ipilimumab infusions, his TSH was very low, but his free T4 is
cortisol and ACTH levels were very low. His MRI of pituitary
ab treatment, his pituitary MRI was normal (A). He was started
ydrocortisone for his central adrenal insufficiency, his pituitary
Immune-related endocrine disorders 255anti-PD1 and anti-CTLA4 induced highest incidence (15%) of
thyroid disorder.7 Intriguingly, in a phase 2 clinical trial of
anti-PDL1 (Atezolizumab), there were no hypophysitis or
thyroid disorders identified.33
Immune checkpoint blockade-associated thyroid disor-
ders could manifest as different types of thyroid disorders
including thyrotoxicosis followed by hypothyroidism34 and
Fig. 2, thyrotoxicosis followed by euthyroidism,35 hypo-
thyroidism,36 Graves hyperthyroidism37 or Graves oph-
thalmopathy.35 Rarely, immune checkpoint blockade
treatment may induce life threatening thyroid-storm.38
Thyrotoxicosis is usually transient and followed by the
development of hypothyroidism as discussed above. Hypo-
thyroidism is permanent in most of the patients who
received anti-PD1 monotherapy or combination therapy
with anti-PD1 and anti-CTLA4 requiring long-term levo-
thyroxine replacement. On the other hand, anti-CTLA4
therapy-related thyroiditis could be reversible.35 Based on
current available data from clinical study34 and our own
practice, immune checkpoint blockade-induced thyroid
disorders are thyroiditis in most of the cases. The man-
agement of thyroid disorder include close monitor the
thyroid function after onset of thyrotoxicosis. Treat the
symptoms of thyrotoxicosis with beta-blocker, i.e.Fig. 2 Timeline of thyroid function in a patient who devel-
oped anti-PD1-related thyroiditis. A 37-year-old female with
history of advanced melanoma who received pembrolizumab
(anti-PD1) treatment and developed thyroid disorders. Prior to
the initiation of anti-PD1 treatment, she had no history of
thyroid disorder. She did well with the first treatment. The
infusion of pembrolizumab was given every 3 weeks. Prior to
her second infusion of pembrolizumab, her routine blood tests
revealed high T4 and suppressed TSH. She reported palpita-
tion, hyperdefecation and 2e3 lbs weight loss over the past 3
weeks. On exam, her heart rate was 99 beats per minutes. She
has not history of cardiovascular disease. She was started with
propranolol 10 mg orally three times daily. Four weeks later,
her repeated tests for thyroid function show overt hypothy-
roidism. She reported gained back her weight and endorsed
fatigue. Propranolol was discontinued. She was started with
levothyroxine replacement. Her autoantibody tests were
negative for both thyroid peroxidase antibody (TPO) and
thyroid-stimulating globulin (TSI). She became clinically and
biochemically euthyroid a few weeks later after a proper
replacement of levothyroxine.propranolol in patients with low risks for cardiovascular
events. High dose glucocorticoid reserves for the patients
with advanced age, severe thyrotoxicosis, thyroid storm,
and the patients with high risks for arrhythmia, and coro-
nary artery disease.Other rare immune checkpoint-inhibition-
related endocrine disorders
A fulminant type 1-like diabetes was reported after the
patient treated with anti-PD1 pembrolizumab.39 This fe-
male patient presented with severe hyperglycemia and
diabetic ketoacidosis as well as elevated lipase 2 weeks
after treated with a second infusion of pembrolizumab.
Subsequent test shows negative autoantibodies (anti-GAD
and anti-IA2). A larger case series reported 5 cases of im-
mune checkpoint inhibition-related type 1-like diabetes.40
Among these 5 patients, 3 had positive anti-GAD65 while
the rest of 2 patients had negative anti-GAD65. Interest-
ingly, 3 of 5 patients had HLA A2.1þ and DR4þ genotype, 4
of 5 patients had HLA DR4þ and 4 of 5 had A2.1þ respec-
tively. The results suggest a correlation between HLA sub-
type and immune checkpoint-inhibition-related type 1-like
diabetes. A grade 4 hypercalcemia was reported in a large
clinical trial but no detail description was given.41
In conclusion, immune checkpoint inhibition therapy has
shown effective and durable tumor responses in different
type of cancers. Endocrine disorders, especially hypo-
physitis and thyroiditis are among most common immune-
related adverse events-induced by immune checkpoint
blockade. With the widespread use of this novel immuno-
therapy against the malignancies, significant amount of the
patients will develop endocrine disorders. Early identifica-
tion and proper management of the endocrine disorders
will improve the outcome of the immune checkpoint inhi-
bition therapy.Conflicts of interest
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